^(131)Ⅰ加抗甲亢药物综合治疗甲亢的临床可行性探讨

The feasible study on clinical Graves′disease treated by ^(131)Ⅰintegration with antithyroid drugs

目的 探讨13 1Ⅰ加抗甲亢药物综合治疗Graves′病甲亢的临床可行性及价值。方法 将 2 6 5例Graves′病甲亢患者随机分为两组 :单纯13 1Ⅰ治疗组 12 3例 ,采用13 1Ⅰ一次性口服治疗 ;13 1Ⅰ加抗甲亢药物治疗组 14 2例 ,在给予13 1Ⅰ一次性口服后第 3天给予抗甲亢药物治疗 1个月 ,比较两组治疗后病情变化情况 ,观察抗甲亢药物对13 1Ⅰ治疗甲亢的疗效影响。结果 治疗 3个月时两组疗效间差别有显著性意义 (P <0 0 1) ,治疗 12个月时两组疗效间差别无显著性意义 (P >0 0 5 )。结论 甲亢患者口服13 1Ⅰ后加用抗甲亢药物治疗不会降低或增加最终疗效 ,对于大多数非重症甲亢患者 ,加用抗甲亢药物并无明显临床价值 ;但对于部分重症患者 ,在口服13 1Ⅰ 3天后加用抗甲亢药物短程治疗则有利于迅速缓解症状 ,平稳度过13

Objective To evaluate the clinical feasibility and value of the therapeutic effectiveness of 131 Ⅰ integration with antithyroid drugs(ATD) on Graves′ disease(GD).Methods 265 cases of GD with hyperthyroidism were divided into two groups at random.The group of 131 Ⅰ simply(123 cases),oral application of 131 Ⅰ only once for all and had no other drugs;the groups of 131 Ⅰ + ATD,short-term treated with ATD for one month beginning the third day after oral application of 131 Ⅰ once for all.The GD activity parameters in two groups were compared after the treatment.The effect of ATD on therapeutic efficacy of 131 Ⅰ in GD were observed.Results There was significant difference in the therapeutic efficacy between two groups(P<0 01) after the treatments 3 months,there was no difference(P>0 05) after 12 months.Conclusion The final efficacy could not be decreased or increased in the treatment of GD with 131 Ⅰ + ATD.ATD is playing no predominant clinical role in most of cases of GD without complications.But the short-term treated with ATD in some cases of GD with complications advantage to relax symptom rapidly,live through calmly the period of time before 131 Ⅰ bring to playing efficacy.